« Back to Record
Trøseid, M., & Hites, M. (2023). Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial. Critical care, 27(1), 9. doi:10.1186/s13054-022-04205-8
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/355982



